Pfizer Must Face Cut Robitussin Labeling Suit


By Hannah Albarazi (Nov 16, 2021, 6:14 PM EST) – Pharmaceutical giant Pfizer won the partial dismissal of a proposed class action lawsuit in New York federal court on Monday, accusing it of misleading consumers with its labeling ” Maximum strength “Robitussin cough syrup, but failed to rule out the lawsuit’s national-class allegations.

U.S. District Judge J. Paul Oetken dismissed unjust enrichment claims from named plaintiffs in Michigan, Colorado, Florida and New York, but declined to dismiss the remainder of the allegations that Pfizer Inc. overcharged consumers for its so-called maximum strength cough medicine, even though it was not stronger than its regular strength counterpart.

Oetken J. called Pfizer’s assertion that …

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas, and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of prosecution, etc.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, requests, etc.
  • Create personalized alerts for specific case articles and topics and more!



Comments are closed.